Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1737, Issue 2-3, 2005, Pages 130-137

  Ribas, Vicent ^a   Palomer, Xavier ^a   Roglans, Núria ^b   Rotllan, Noemi ^a   Fievet, Catherine ^c   Tailleux, Anne ^c   Julve, Josep ^a   Laguna, Joan Carles ^b   Blanco Vaca, Francisco ^a   Escolà Gil, Joan Carles ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSERM   (France)

Author keywords

Apolipoprotein A II; Familial combined hyperlipidemia; Fibrate; Peroxisome proliferator activated receptor ; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOENZYME; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG MECHANISM; FATTY ACID OXIDATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HYDROLYSIS; HYPERLIPIDEMIA; IN VIVO STUDY; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-II; BASE SEQUENCE; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, TRANSGENIC; PPAR ALPHA; PROCETOFEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

ANIMALIA; MUS MUSCULUS;

EID: 28444484300     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2005.09.009     Document Type: Article

References (48)

1. J.C. Fruchart, P. Duriez, and B. Staels Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis Curr. Opin. Lipidol. 10 1999 245 257
2. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
3. J. Auwerx, K. Schoonjans, J.C. Fruchart, and B. Staels Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects J. Atheroscler. Thromb. 3 1996 81 89
4. A. Tailleux, G. Torpier, H. Mezdour, J.C. Fruchart, B. Staels, and C. Fievet Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis Trends Pharmacol. Sci. 24 2003 530 534
5. P.M. Sullivan, H. Mezdour, S.H. Quarfordt, and N. Maeda Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2 J. Clin. Invest. 102 1998 130 135
6. M. Yoon, S. Jeong, C.J. Nicol, H. Lee, M. Han, J.J. Kim, Y.J. Seo, C. Ryu, and G.T. Oh Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism Exp. Mol. Med. 34 2002 481 488
7. S. Jeong, M. Han, H. Lee, M. Kim, J. Kim, C.J. Nicol, B.H. Kim, J.H. Choi, K.H. Nam, G.T. Oh, and M. Yoon Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice Metabolism 53 2004 1284 1289
8. T. Fu, P. Kashireddy, and J. Borensztajn The peroxisome-proliferator- activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E Biochem. J. 373 2003 941 947
9. T. Fu, D. Mukhopadhyay, N.O. Davidson, and J. Borensztajn The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions J. Biol. Chem. 279 2004 28662 28669
10. M. Yoon, S. Jeong, H. Lee, M. Han, J.H. Kang, E.Y. Kim, M. Kim, and G.T. Oh Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice Biochem. Biophys. Res. Commun. 302 2003 29 34
11. H. Duez, Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fievet, S.D. Wright, and B. Staels Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice J. Biol. Chem. 277 2002 48051 48057
12. F. Blanco-Vaca, J.C. Escola-Gil, J.M. Martin-Campos, and J. Julve Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein J. Lipid Res. 42 2001 1727 1739
13. A. Tailleux, P. Duriez, J.C. Fruchart, and V. Clavey Apolipoprotein A-II, HDL metabolism and atherosclerosis Atherosclerosis 164 2002 1 13
14. A.D. Kalopissis, D. Pastier, and J. Chambaz Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance Curr. Opin. Lipidol. 14 2003 165 172
15. J.M. Martin-Campos, J.C. Escola-Gil, V. Ribas, and F. Blanco-Vaca Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility Curr. Opin. Lipidol. 15 2004 247 253
16. J. Julve, J.C. Escola-Gil, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre, and F. Blanco-Vaca Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet Biochim. Biophys. Acta 1488 2000 233 244
17. J.C. Escola-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre, and F. Blanco-Vaca Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia J. Lipid Res. 41 2000 1328 1338
18. M. Guerre-Millo, C. Rouault, P. Poulain, J. Andre, V. Poitout, J.M. Peters, F.J. Gonzalez, J.C. Fruchart, G. Reach, and B. Staels PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance Diabetes 50 2001 2809 2814
19. K. Tordjman, C. Bernal-Mizrachi, L. Zemany, S. Weng, C. Feng, F. Zhang, T.C. Leone, T. Coleman, D.P. Kelly, and C.F. Semenkovich PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice J. Clin. Invest. 107 2001 1025 1034
20. A. Marzal-Casacuberta, F. Blanco-Vaca, B.Y. Ishida, J. Julve-Gil, J. Shen, S. Calvet-Marquez, F. Gonzalez-Sastre, and L. Chan Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II J. Biol. Chem. 271 1996 6720 6728
21. N.R. Council Guide for the Care and Use of Laboratory Animals 1985 23 85 rev.
22. J.C. Escola-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre, and F. Blanco-Vaca ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance J. Lipid Res. 42 2001 241 248
23. R.R. Singaraja, C. Fievet, G. Castro, E.R. James, N. Hennuyer, S.M. Clee, N. Bissada, J.C. Choy, J.C. Fruchart, B.M. McManus, B. Staels, and M.R. Hayden Increased ABCA1 activity protects against atherosclerosis J. Clin. Invest. 110 2002 35 42
24. N. Roglans, E. Sanguino, C. Peris, M. Alegret, M. Vazquez, T. Adzet, C. Diaz, G. Hernandez, J.C. Laguna, and R.M. Sanchez Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats J. Pharmacol. Exp. Ther. 302 2002 232 239
25. M.C. Jong, V.E. Dahlmans, M.H. Hofker, and L.M. Havekes Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner Biochem. J. 328 Pt. 3 1997 745 750
26. A. Tailleux, M. Bouly, G. Luc, G. Castro, J.M. Caillaud, N. Hennuyer, P. Poulain, J.C. Fruchart, N. Duverger, and C. Fievet Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice Arterioscler. Thromb. Vasc. Biol. 20 2000 2453 2458
27. E. Boisfer, G. Lambert, V. Atger, N.Q. Tran, D. Pastier, C. Benetollo, J.F. Trottier, I. Beaucamps, M. Antonucci, M. Laplaud, S. Griglio, J. Chambaz, and A.D. Kalopissis Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis J. Biol. Chem. 274 1999 11564 11572
28. P. Alaupovic, C. Knight-Gibson, C.S. Wang, D. Downs, E. Koren, H.B. Brewer Jr., and R.E. Gregg Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia J. Lipid Res. 32 1991 9 19
29. C.S. Wang, P. Alaupovic, R.E. Gregg, and H.B. Brewer Jr. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes Biochim. Biophys. Acta 920 1987 9 19
30. L. Berthou, N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J.C. Fruchart, E. Rubin, P. Denefle, B. Staels, and D. Branellec Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice J. Clin. Invest. 97 1996 2408 2416
31. S.M. Post, R. de Crom, R. van Haperen, A. van Tol, and H.M. Princen Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein Arterioscler. Thromb. Vasc. Biol. 23 2003 892 897
32. L. Berthou, R. Saladin, P. Yaqoob, D. Branellec, P. Calder, J.C. Fruchart, P. Denefle, J. Auwerx, and B. Staels Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids Eur. J. Biochem. 232 1995 179 187
33. A.R. Tall, and D.M. Small Plasma high-density lipoproteins N. Engl. J. Med. 299 1978 1232 1236
34. E. Voyiaziakis, I.J. Goldberg, A.S. Plump, E.M. Rubin, J.L. Breslow, and L.S. Huang ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice J. Lipid Res. 39 1998 313 321
35. N. Vu-Dac, K. Schoonjans, V. Kosykh, J. Dallongeville, J.C. Fruchart, B. Staels, and J. Auwerx Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor J. Clin. Invest. 96 1995 741 750
36. K. Schoonjans, B. Staels, and J. Auwerx Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression J. Lipid Res. 37 1996 907 925
37. Q. Guo, P.R. Wang, D.P. Milot, M.C. Ippolito, M. Hernandez, C.A. Burton, S.D. Wright, and Y. Chao Regulation of lipid metabolism and gene expression by fenofibrate in hamsters Biochim. Biophys. Acta 1533 2001 220 232
38. P.D. Cornwell, A.T. De Souza, and R.G. Ulrich Profiling of hepatic gene expression in rats treated with fibric acid analogs Mutat. Res. 549 2004 131 145
39. M. Guerre-Millo, P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J.M. Herbert, D.A. Winegar, T.M. Willson, J.C. Fruchart, R.K. Berge, and B. Staels Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity J. Biol. Chem. 275 2000 16638 16642
40. S.L. Dana, P.A. Hoener, J.M. Bilakovics, D.L. Crombie, K.M. Ogilvie, R.F. Kauffman, R. Mukherjee, and J.R. Paterniti Jr. Peroxisome proliferator- activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat Metabolism 50 2001 963 971
41. J. Dallongeville, E. Bauge, A. Tailleux, J.M. Peters, F.J. Gonzalez, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil J. Biol. Chem. 276 2001 4634 4639
42. M. Bouly, D. Masson, B. Gross, X.C. Jiang, C. Fievet, G. Castro, A.R. Tall, J.C. Fruchart, B. Staels, L. Lagrost, and G. Luc Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate J. Biol. Chem. 276 2001 25841 25847
43. H. Nakshatri, and P. Bhat-Nakshatri Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements Nucleic Acids Res. 26 1998 2491 2499
44. P. Puigserver, and B.M. Spiegelman Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator Endocr. Rev. 24 2003 78 90
45. M.B. Sandberg, M. Bloksgaard, D. Duran-Sandoval, C. Duval, B. Staels, and S. Mandrup The gene encoding acyl-CoA-binding protein is subject to metabolic regulation by both sterol regulatory element-binding protein and peroxisome proliferator-activated receptor alpha in hepatocytes J. Biol. Chem. 280 2005 5258 5266
46. M.H. Doolittle, R.C. LeBoeuf, C.H. Warden, L.M. Bee, and A.J. Lusis A polymorphism affecting apolipoprotein A-II translational efficiency determines high density lipoprotein size and composition J. Biol. Chem. 265 1990 16380 16388
47. K. Ikewaki, L.A. Zech, M. Kindt, H.B. Brewer Jr., and D.J. Rader Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans Arterioscler. Thromb. Vasc. Biol. 15 1995 306 312
48. J. Julve, J.C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J.L. Sanchez-Quesada, and F. Blanco-Vaca Mechanisms of HDL deficiency in mice overexpressing human apoA-II J. Lipid Res. 43 2002 1734 1742